RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections
Johann Motsch, Cláudia Murta de Oliveira, Viktor Stus, Iftihar Köksal, Olexiy Lyulko, Helen W Boucher, Keith S Kaye, Thomas M File, Michelle L Brown, Ireen Khan, Jiejun Du, Hee-Koung Joeng, Robert W Tipping, Angela Aggrey, Katherine Young, Nicholas A Kartsonis, Joan R Butterton, Amanda Paschke, Johann Motsch, Cláudia Murta de Oliveira, Viktor Stus, Iftihar Köksal, Olexiy Lyulko, Helen W Boucher, Keith S Kaye, Thomas M File, Michelle L Brown, Ireen Khan, Jiejun Du, Hee-Koung Joeng, Robert W Tipping, Angela Aggrey, Katherine Young, Nicholas A Kartsonis, Joan R Butterton, Amanda Paschke
Abstract
Background: The β-lactamase inhibitor relebactam can restore imipenem activity against imipenem-nonsusceptible gram-negative pathogens. We evaluated imipenem/relebactam for treating imipenem-nonsusceptible infections.
Methods: Randomized, controlled, double-blind, phase 3 trial. Hospitalized patients with hospital-acquired/ventilator-associated pneumonia, complicated intraabdominal infection, or complicated urinary tract infection caused by imipenem-nonsusceptible (but colistin- and imipenem/relebactam-susceptible) pathogens were randomized 2:1 to 5-21 days imipenem/relebactam or colistin+imipenem. Primary endpoint: favorable overall response (defined by relevant endpoints for each infection type) in the modified microbiologic intent-to-treat (mMITT) population (qualifying baseline pathogen and ≥1 dose study treatment). Secondary endpoints: clinical response, all-cause mortality, and treatment-emergent nephrotoxicity. Safety analyses included patients with ≥1 dose study treatment.
Results: Thirty-one patients received imipenem/relebactam and 16 colistin+imipenem. Among mITT patients (n = 21 imipenem/relebactam, n = 10 colistin+imipenem), 29% had Acute Physiology and Chronic Health Evaluation II scores >15, 23% had creatinine clearance <60 mL/min, and 35% were aged ≥65 years. Qualifying baseline pathogens: Pseudomonas aeruginosa (77%), Klebsiella spp. (16%), other Enterobacteriaceae (6%). Favorable overall response was observed in 71% imipenem/relebactam and 70% colistin+imipenem patients (90% confidence interval [CI] for difference, -27.5, 21.4), day 28 favorable clinical response in 71% and 40% (90% CI, 1.3, 51.5), and 28-day mortality in 10% and 30% (90% CI, -46.4, 6.7), respectively. Serious adverse events (AEs) occurred in 10% of imipenem/relebactam and 31% of colistin+imipenem patients, drug-related AEs in 16% and 31% (no drug-related deaths), and treatment-emergent nephrotoxicity in 10% and 56% (P = .002), respectively.
Conclusions: Imipenem/relebactam is an efficacious and well-tolerated treatment option for carbapenem-nonsusceptible infections.
Clinical trials registration: NCT02452047.
Keywords: KPC; cIAI; cUTI; carbapenem resistant; nosocomial pneumonia.
© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America.
Figures
References
- Munoz-Price LS, Poirel L, Bonomo RA, et al. . Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis 2013; 13:785–96.
- Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2013. Available at: . Accessed 3 June 2019.
- Cerceo E, Deitelzweig SB, Sherman BM, Amin AN. Multidrug-resistant gram-negative bacterial infections in the hospital setting: overview, implications for clinical practice, and emerging treatment options. Microb Drug Resist 2016; 22:412–31.
- World Health Organization. Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. 2017. Available at:
- Zilberberg MD, Shorr AF, Micek ST, Vazquez-Guillamet C, Kollef MH. Multi-drug resistance, inappropriate initial antibiotic therapy and mortality in gram-negative severe sepsis and septic shock: a retrospective cohort study. Crit Care 2014; 18:596.
- Livermore DM, Warner M, Mushtaq S. Activity of MK-7655 combined with imipenem against Enterobacteriaceae and Pseudomonas aeruginosa. J Antimicrob Chemother 2013; 68:2286–90.
- Rizk ML, Rhee EG, Jumes PA, et al. . Intrapulmonary pharmacokinetics of relebactam, a novel beta-lactamase inhibitor, dosed in combination with imipenem-cilastatin in healthy subjects. Antimicrob Agents Chemother 2018; 62.:e01411–17.
- Rizk ML, Jumes P, Lasseter K, et al. . Pharmacokinetics of MK-7655, a novel b-lactamase inhibitor (BLI), in combination with imipenem/cilastatin (IPM/CIL) in subjects with impaired renal function. In: 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). San Francisco, CA, 2012; A-010.
- Karlowsky JA, Lob SH, Kazmierczak KM, et al. . In vitro activity of imipenem/relebactam against gram-negative ESKAPE pathogens isolated in 17 European countries: 2015 SMART surveillance programme. J Antimicrob Chemother 2018; 73:1872–9.
- Papp-Wallace KM, Barnes MD, Alsop J, et al. . Relebactam is a potent inhibitor of the KPC-2 beta-lactamase and restores the susceptibility of imipenem against KPC-producing Enterobacteriaceae. Antimicrob Agents Chemother 2018; 62:e00174–18.
- Lucasti C, Vasile L, Sandesc D, et al. . Phase 2, dose-ranging study of relebactam with imipenem-cilastatin in subjects with complicated intra-abdominal infection. Antimicrob Agents Chemother 2016; 60:6234–43.
- Sims M, Mariyanovski V, McLeroth P, et al. . Prospective, randomized, double-blind, phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections. J Antimicrob Chemother 2017; 72:2616–26.
- Wu J, Racine F, Wismer MK, et al. . Exploring the pharmacokinetic/pharmacodynamic relationship of relebactam (MK-7655) in combination with imipenem in a hollow-fiber infection model. Antimicrob Agents Chemother 2018; 62:e02323–17.
- Clinical and Laboratory Standards Institute. M07-A10. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard. Wayne, PA: CLSI, 2015.
- Clinical and Laboratory Standards Institute. M100-S27. Performance standards for antimicrobial susceptibility testing. 27 ed. Wayne, PA: CLSI, 2017.
- US Department of Health and Human Services, Food and Drug Administration Center for Drug Evaluation and Research. Community-acquired bacterial pneumonia: developing drugs for treatment, guidance for industry. Silver Spring, MD: Center for Drug Evaluation and Research, 2014.
- US Department of Health and Human Services, Food and Drug Administration Center for Drug Evaluation and Research. Guidance for industry. Complicated intra-abdominal infections: developing drugs for treatment. Silver Spring, MD: Center for Drug Evaluation and Research, 2018.
- US Department of Health and Human Services, Food and Drug Administration Center for Drug Evaluation and Research. Guidance for industry. Complicated urinary tract infections: developing drugs for treatment. Silver Spring, MD: Center for Drug Evaluation and Research, 2015.
- Shortridge D, Pfaller MA, Castanheira M, Flamm RK. Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. hospitals (2013–2016) as part of the surveillance program: program to assess ceftolozane-tazobactam susceptibility. Microb Drug Resist 2018; 24:563–77.
- Lapuebla A, Abdallah M, Olafisoye O, et al. . Activity of meropenem combined with RPX7009, a novel β-lactamase inhibitor, against gram-negative clinical isolates in New York City. Antimicrob Agents Chemother 2015; 59:4856–60.
- Hawkey PM, Warren RE, Livermore DM, et al. . Treatment of infections caused by multidrug-resistant gram-negative bacteria: report of the British Society for Antimicrobial Chemotherapy/Healthcare Infection Society/British Infection Association Joint Working Party. J Antimicrob Chemother 2018; 73(suppl 3):iii2–78.
- Solomkin JS, Mazuski JE, Bradley JS, et al. . Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis 2010; 50:133–64.
- Kalil AC, Metersky ML, Klompas M, et al. . Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis 2016; 63:e61–e111.
- Freifeld AG, Bow EJ, Sepkowitz KA, et al. . Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2011; 52:e56–93.
- Tsuji BT, Pogue JM, Zavascki AP, et al. . International consensus guidelines for the optimal use of the polymyxins: endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). Pharmacotherapy 2019; 39:10–39.
- Lee YJ, Wi YM, Kwon YJ, Kim SR, Chang SH, Cho S. Association between colistin dose and development of nephrotoxicity. Crit Care Med 2015; 43:1187–93.
- Carrara E, Bragantini D, Tacconelli E. Combination versus monotherapy for the treatment of infections due to carbapenem-resistant Enterobacteriaceae. Curr Opin Infect Dis 2018; 31:594–9.
- Chalhoub H, Sáenz Y, Rodriguez-Villalobos H, et al. . High-level resistance to meropenem in clinical isolates of Pseudomonas aeruginosa in the absence of carbapenemases: role of active efflux and porin alterations. Int J Antimicrob Agents 2016; 48:740–3.
- Melinta Therapeutics Inc. Vabomere (meropenem and vaborbactam for injection. Prescribing information. Lincolnshire, IL: Melinta Therapeutics Inc, 2018.
- European Centre for Disease Prevention and Control. Rapid risk assessment: emergence of resistance to ceftazidime-avibactam in carbapenem-resistant Enterobacteriaceae. Solna, Sweden: European Centre for Disease Prevention and Control, 2018.
- Chalhoub H, Tulkens, PM, Van Bambeke F. Avibactam is a substrate for Mex-AB-OprM in Pseudomonas aeruginosa. In: 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). Vienna, Austria, 2017.
- Garonzik SM, Li J, Thamlikitkul V, et al. . Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother 2011; 55:3284–94.
- Nation RL, Garonzik SM, Li J, et al. . Updated US and European dose recommendations for intravenous colistin: how do they perform? Clin Infect Dis 2016; 62:552–8.
- Rex JH, Pfaller MA. Has antifungal susceptibility testing come of age? Clin Infect Dis 2002; 35:982–9.
- Merck & Co Inc. PRIMAXIN® I.V. (imipenem and cilastatin for injection). Last revised October 2014 ed. Merck & Co., Inc., Whitehouse Station, NJ, 2014.
- Brown ML, Motsch J, Kaye KS, et al. . Nephrotoxicity associated with imipenem/cilastatin/relebactam (IMI/REL) versus imipenem/cilastatin plus colistin (IMI+CST) in patients with imipenem-nonsusceptible (NS) bacterial infections. In: IDWeek. San Francisco, CA, 2018.
Source: PubMed